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bodies, amyloid fibrils and folding aggregates.
Substantial data support the hypothesis that partially
folded intermediates are key precursors to aggregates,
that aggregation involves specific intermolecular
interactions and that most aggregates involve βb sheets.
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Introduction
Protein aggregation can be merely a nuisance factor in
many in vitro studies of proteins or it can cause major
economic and technical problems in the biotechnology
and pharmaceutical industries. Its effects can be lethal in
patients who suffer from a variety of diseases involving
protein aggregation, such as the amyloidoses, prion dis-
eases and other protein deposition disorders [1,2]. This
review focuses on the basic mechanism(s) of protein aggre-
gation, the factors that determine whether it will occur,
and the conformation of the protein molecules in the
aggregate. Protein aggregation is intimately tied to protein
folding and stability, and also, in the cell, to molecular
chaperones. The prevalence of protein aggregation is
probably much higher than generally realized — it is often
ignored or worked around, and in protein folding experi-
ments its presence may not even be realized [3]. The
growing recognition of the critical importance of protein
aggregation has resulted in a number of reviews [4–10].
Unless specifically noted to the contrary, in this review
the term aggregation will apply to aggregated protein
involving the formation of insoluble precipitates that may
be considered ‘pathological’ in nature. This is in contrast
to the insolubility of the native state due to protein con-
centrations exceeding the solubility limit (e.g. ‘salting
out’), or the intermolecular association involved in the for-
mation of native oligomers. It should be noted that in
many such cases of pathological aggregation the initial
material formed may be soluble aggregates, but these
become insoluble when they exceed a certain size.
It is convenient to classify protein aggregation according
to the following categories: in vivo and in vitro, and
ordered and disordered. Amyloid fibrils (both in vivo and
in vitro) are examples of ordered aggregates, whereas
inclusion bodies are examples of in vivo disordered aggre-
gates. Corresponding disordered in vitro aggregates are
those formed during the refolding of denaturant-unfolded
protein at high protein concentrations, or under weakly
native conditions at high protein concentration; these will
be referred to as folding aggregates.
Native, folded proteins may aggregate under certain con-
ditions, most notably salting out and isoelectric precipita-
tion (when the net charge on the protein is zero). Such
precipitates of native protein are readily distinguished
from pathological aggregates by their solubility in buffer
under native-like conditions. In contrast, pathological
aggregates dissociate and dissolve only in the presence of
high concentrations of denaturant or detergent. In my lab-
oratory, it has been shown that the native conformation is
retained in salting out precipitates (Figure 1).
Protein aggregation has usually been assumed to involve
either unfolded or native states. Inclusion body formation
and other aggregates formed during protein folding have
been assumed to arise from hydrophobic aggregation of
the unfolded or denatured states, whereas amyloid fibrils
and other extracellular aggregates have been assumed to
arise from native-like conformations in a process analo-
gous to the polymerization of hemoglobin S [8]. Recent
observations suggest that aggregation is much more likely
to arise from specific partially folded intermediates,
however. An important consequence of this is that aggre-
gation will be favored by factors and conditions that favor
population of these intermediates, and hence it is the
properties of these intermediates that are important in
determining whether aggregation occurs. Furthermore,
the characteristics and properties of the intermediates may
be significantly different from those of the native (and
unfolded) conformation.
Several observations indicate that transient aggregation
occurring during in vitro protein refolding may be mis-
taken for a transient intermediate [3]. Direct evidence for
the transient association of partially folded intermediates
during refolding has been obtained in small-angle X-ray
scattering experiments of apomyoglobin [11,12], carbonic
anhydrase and phosphoglycerate kinase [13]. The experi-
ments show the rapid (milliseconds or less) formation of
associated states that become monomeric on a slow time-
scale (typically seconds to minutes or longer). Another
approach indicative of transient aggregation is that involv-
ing changes in the rate constants for refolding as a function
of protein concentration [3]. This study indicates that tran-
sient aggregates can easily be mistaken for structured
monomers and could be a general problem in time-resolved
folding studies. Because aggregation is sensitive to protein
concentration, monitoring the kinetics as a function of
concentration should reveal potential aggregation artifacts.
Key questions relating to aggregation, many of which are
not yet fully answered, include the following: the nature
of the species responsible for aggregation: the detailed
mechanism that leads to aggregation and the underlying
kinetics scheme; the structure of the aggregates; the speci-
ficity of the intermolecular interaction (e.g. are the aggre-
gates homogenous?); why aggregation (even of the same
protein) sometimes leads to ordered aggregates (amyloid)
and sometimes to disordered aggregates (inclusion bodies,
folding aggregates and amorphous deposits); how the envi-
ronmental conditions affect the rate and the amount of
aggregation; and how the aggregation may be prevented.
It seems likely from an evolutionary perspective that pro-
teins have evolved to avoid sequences that result in a
strong propensity to aggregate. It is also interesting to con-
sider that many short peptide sequences containing several
hydrophobic residues and a high tendency for β-sheet
formation probably have a strong disposition to form
aggregates and/or amyloid fibrils. It is only the flanking
sequences, which are either quite polar and therefore
increase the solubility limit or are sufficiently bulky to
sterically prevent the required interactions, that result in
the lack of aggregation and/or amyloid formation.
Problems due to protein aggregation
Protein deposition diseases
Several dozen protein deposition diseases are known.
The most familiar include the amyloid diseases (amyloid-
oses), such as Alzheimer’s disease, and the transmissible
spongiform encephalopathies (TSEs; prion diseases such
as bovine spongiform encephalopathy, BSE, or Mad Cow
disease and Creutzfeldt–Jacob disease, CJD, in humans).
In both amyloid and prion diseases the aggregated pro-
tein is usually in the form of ordered fibrils. Amyloid fibril
formation has been observed to arise from both peptides
and proteins. Several protein deposition diseases involve
non-ordered protein deposits; some examples are inclu-
sion body myositis, light-chain deposition disease and
cataracts. Many thousands of people die each year from
protein deposition diseases [14]. New diseases are added
to this list every year, one of the latest being Huntington’s
disease [15].
Inclusion bodies
Inclusion body formation is very common when proteins
are overexpressed. This may facilitate their potential
purification because inclusion bodies are usually highly
homogeneous. The problem is that renaturation is fre-
quently difficult, as a result of aggregation. Several tech-
niques have been developed to help overcome the
common problem of their re-aggregation during renatura-
tion [16] and some are discussed later. Inclusion bodies
and related insoluble non-ordered protein aggregates are
also found in certain diseases.
Protein drugs
Protein aggregation is also a problem in a number of other
aspects of biotechnology; for example, during storage or
delivery of protein drugs. There are several reports that
protein aggregation can occur during lyophilization of pro-
teins or during their subsequent rehydration, depending
on the conditions (e.g. the water content of the system is
critical [17–22]). Because in some cases it appears that the
dehydration of proteins, which occurs in lyophilization,
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Figure 1
Precipitates of native protein, in this case interleukin-2 (IL-2) formed by
‘salting out’ with ammonium sulfate, retain the native conformation. The
figure shows the second derivatives of the FTIR spectra of the amide I
region of native, ammonium sulfate precipitated IL-2 (dashed line) and,
for comparison, aggregated (inclusion body) IL-2 (dotted line). IL-2 is
an all-α protein, as indicated by the dominant band at 1654 cm–1 for
the native conformation.
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results in denaturation [23,24], it is probably the ensuing
rehydration that leads to aggregation, due to the forma-
tion of partially folded intermediates during the refolding
(see below).
Mechanisms of aggregation
One of the earliest and most prescient studies of protein
aggregation was that of Goldberg and coworkers [25] on
the enzyme tryptophanase, which revealed an intermedi-
ate at moderate denaturant concentration that aggregated.
Evidence for the potential specificity of aggregation was
also observed in that the addition of other folded proteins
did not affect the amount of aggregated tryptophanase.
More recently, the idea that partially folded intermediates
might be responsible for aggregation has been championed
by King and coworkers [4,26,27] and Wetzel [6,8,10,28].
Recent reports supporting the involvement of partially
folded intermediates in the aggregation of several proteins
suggests the generality of the phenomenon [29–31]. 
Hypothesis
Substantial data support the following model for the for-
mation and structure of protein aggregates, in which spe-
cific intermolecular interactions between hydrophobic
surfaces of structural subunits in partially folded interme-
diates are responsible for the aggregation. Key features of
the model (Figure 2) are as follows. Protein folding
involves intermediates, each consisting of an ensemble of
closely related substates (the various substates of a given
intermediate will be characterized by having common sec-
ondary structure and most likely a common core of rela-
tively native-like structure, with the remainder of the
polypeptide chain disordered or in unstable structural
units). The native state is formed by the sequential inter-
action of substructural units, the building blocks (typically
subdomains), which may be stable or metastable on their
own, but are stabilized by the interactions with other such
building blocks [32]. Formation of the native state
involves the intramolecular interaction of the hydrophobic
faces of structural subunits (Figure 3a). Specificity will
arise from a variety of features, of which the geometric
shape and extent of the hydrophobic patches, the con-
straints of the polypeptide chain, and the presence of
other structural subunits are probably the most important.
Aggregation occurs when these hydrophobic surfaces
interact in an intermolecular manner (Figure 3b). Thus,
the initial stages of aggregation are quite specific in the
sense that they involve the interaction of specific surface
elements of the structural subunits of one molecule with
‘matching’ hydrophobic surface areas of structural sub-
units of a neighboring molecule. Three-dimensional prop-
agation of this process leads to large aggregates. Initially,
the aggregates (e.g. dimers and tetramers) will be soluble,
but eventually their size will exceed the solubility limit.
The fact that they may still have significant solvent-
exposed hydrophobic surfaces would also minimize their
solubility. The intermediates are more prone to aggregate
than the unfolded state because in the unfolded state the
hydrophobic sidechains are scattered relatively randomly
in many small hydrophobic regions, whereas in the par-
tially folded intermediates there will be large patches of
contiguous surface hydrophobicity, which will have a
much stronger propensity for aggregation (these are the
surfaces that ‘normally’ interact in an intramolecular
manner to form the native conformation). The role of
domain (or subdomain) swapping [33] in aggregation is
unclear, but it is certainly possible that in some cases it
may be an important factor.
Aggregation often appears to be irreversible, but this is
usually a reflection of the very slow rates of disaggregation
and the fact that the equilibrium lies far in favor of the
aggregate rather than its soluble monomeric form. Under
certain conditions, aggregates, including in vivo amyloid
deposits, can be reversed [34,35]. In practice, however,
once insoluble aggregates form, the process is effectively
irreversible under native-like conditions. 
A number of observations suggest that specific inter-
actions are involved in protein aggregation. Among the
clearest evidence for such specificity is the work of
Brems and coworkers [36–40] with bovine growth hor-
mone (bGH), which showed that a peptide fragment
of bGH could inhibit aggregation and that mutations,
which increased the hydrophobicity of the domain inter-
face, increased the propensity for aggregation. Another
strong indication of specificity in aggregation is the
homogeneity of inclusion bodies [41], which are normally
highly homogeneous once any contaminating material has
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Figure 2
The basic model for protein aggregation. The circled I represents a key
partially folded intermediate, which can be populated either in the
folding direction (from unfolded) or from the native state. The
intermediate I has a strong propensity to aggregate, leading to either
ordered or disordered (amorphous) aggregates. It is possible that
there is very local order even in apparently (macroscopically)
amorphous aggregates. Intermediate I will normally be an intermediate
on both the in vivo and in vitro folding pathways.
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been removed [41]. Similar arguments apply to amyloid
fibril formation.
Factors favoring aggregation
Circumstances that lead to the population of partially
folded intermediates, especially if their concentration is
high, are thus likely to lead to aggregation; these circum-
stances include mutations that lead to differential destabi-
lization of the native state relative to the partially folded
intermediate, as well as environmental conditions. Conse-
quently, the major factors that determine whether a
protein will aggregate, and the extent and rate of the
aggregation, are: the protein amino acid sequence, the
pH, the temperature and ionic strength, the concentration
of the protein, the presence of cosolutes (e.g. denaturants
such as urea, other chaotropes or kosmotropes — includ-
ing osmolytes — and ligands that interact selectively with
either the native or non-native conformations of the pro-
tein or the aggregated form), and the presence (or absence)
of various molecular chaperones. In fact, a major role of
chaperones is to prevent the potential aggregation of newly
synthesized proteins, or those denatured through stress.
In most instances of aggregation, especially in vivo, there
is a kinetic competition between aggregation and other
processes, such as folding (Figure 4). The environmental
conditions and the protein concentration significantly affect
the degree and rate of intermolecular association. The
protein concentration enters the equation because aggre-
gation minimally involves a second-order kinetic process
(although the growth of amyloid fibrils, and other aggre-
gates, may appear first order). In the context of physiologi-
cal aggregation, the potential role of post-translational
processing may be critical. It is likely that in many cases
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Figure 3
Proposed mechanisms for aggregation
involving structural building blocks
(subdomains). See text for more details.
(a) The normal folding situation, in which
hydrophobic surfaces (black) of the structural
units interact in an intramolecular manner to
form the native conformation. Each identifiable
intermediate along the pathway will consist of
an ensemble of substates, having in common
the compact structural unit(s), with the
remainder of the chain in a disordered or
unstable structured form. (b) The situation in
which aggregation occurs by intermolecular
interaction of the structural building blocks,
again via interaction of complementary
hydrophobic surfaces. The common
intermediate in folding and aggregation can
be seen.
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when aggregation occurs from a solution of the native
protein it is the partially folded intermediates in equilib-
rium with the native state that are the immediate precursors
of the aggregates.
The hypothesis that aggregation arises from partially
folded intermediates explains the apparent lack of correla-
tion between protein stability and aggregation that is some-
times observed [42]. Thus, if the decreased stability of the
native state of a mutant form also destabilizes the partially
folded intermediate that is responsible for aggregation then
a correlation may be observed. On the other hand, if desta-
bilization of the native conformation increases the popula-
tion of a partially folded intermediate that aggregates then
increased aggregation will be observed and there will be no
apparent correlation with the native-state stability.
The propensity for a given protein to aggregate, either in
vivo or in vitro, may well be determined in part by the
lifetime of partially folded intermediates. Longer lived
intermediates are more likely to lead to aggregation for
two reasons: first, there is a greater chance of interaction
with another such partially folded intermediate, and
second, in the in vivo situation, the molecular chaper-
ones involved in preventing aggregation by sequestering
the partially folded intermediate may become saturated,
and thus there will not be enough free chaperones avail-
able to bind to additional newly synthesized protein.
Several observations indicate that in vivo and in vitro
aggregation during folding give rise to similar aggregates,
suggesting that it is likely that a common partially folded
intermediate is responsible for both types of aggregates
[26,30,43,44].
In vivo aggregates: inclusion bodies 
It is noteworthy that inclusion body formation is found
not only in prokaryote and eukaryote cells, but also for
both heterologous and homologous overexpression. This
emphasizes that it is the overexpression itself that is
responsible for the aggregation. For example, in vivo
aggregation of β-lactamase is only observed when the rate
of expression exceeds 2.5% of the total protein synthesis
rate [45,46]. This mirrors the observations with in vitro
refolding systems, which show that aggregation increases
as the protein concentration increases [44]. Despite the
fundamental and practical importance of inclusion bodies,
rather little is known about their structures and mecha-
nisms of formation. No correlation has been found
between inclusion body formation in recombinant pro-
teins and a wide variety of factors, including size and
hydrophobicity, although some correlation with average
charge and fraction of turn-forming residues has been
observed [47]. Inclusion bodies are frequently refractory
to renaturation. To obtain functional protein requires
denaturation and solubilization, often with disulfide
reducing agents, and subsequent renaturation. It is fre-
quently observed that the only way to renature significant
amounts of soluble material is to use extremely low pro-
tein concentrations to avoid aggregation. As a result, inclu-
sion bodies are a major problem in biotechnology and the
development of protein drugs [48].
Although many inclusion bodies are refractile in phase
contrast microscopy, some large insoluble aggregates in
Escherichia coli are not refractile, and have been called
‘floccule-type’ inclusion bodies [49]. At least in some
cases, these appear to be less tightly packed, and more
easily solubilized than classical inclusion bodies. It is pos-
sible that these aggregates arise from native protein of
very limited solubility, rather than partially folded inter-
mediates. We have noticed that there is a range in the
denaturant solubility of in vivo insoluble proteins: classi-
cal inclusion bodies are relatively resistant to solubiliza-
tion, whereas some insoluble material is much more
readily dissolved in denaturant and is clearly morphologi-
cally different (S. Seshadri and A.L.F., unpublished
observations). Morphological differences have also been
observed between cytoplasmic and periplasmic inclusion
bodies, reflected in differences in denaturant solubility
and protease resistance [50].
Several factors have been suggested to lead to inclusion
body formation, including: the high local concentration
of protein; a reducing environment in the cytoplasm; lack
of post-translational modifications; improper interactions
with chaperones and other enzymes involved in in vivo
folding; and intermolecular crosslinking via disulfides
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Figure 4
Aggregation usually involves kinetic competition. During in vivo protein
synthesis, for example, partially folded intermediates are divided
between pathways leading to spontaneous folding and the native state,
aggregation, binding to chaperones and proteolytic degradation.
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(although inclusion bodies can form from proteins
lacking cysteine). Three possible mechanisms for inclu-
sion body formation have been proposed: aggregation of
native protein of limited solubility; aggregation of the
unfolded state; and aggregation of partially folded inter-
mediate states. Until recently, there was no evidence for
any regular structure in inclusion bodies and the prevail-
ing view was that inclusion body formation was an aggre-
gation process mediated by non-specific interactions in
the unfolded state [10].
In a series of elegant studies on the tailspike endorhamno-
sidase of phage P22, King and coworkers [43,51–55] have
shown that partially folded intermediates are responsible
for the aggregation of tailspike protein as well as inclusion
body formation in this unique system. Their results are
consistent with a model in which aggregate formation,
both in vivo and in vitro, occurs by the specific association
of a partially folded intermediate that associates preferen-
tially in an intermolecular fashion to form aggregates,
rather than intramolecular association leading to the native
conformation. A series of multimeric partially folded inter-
mediates, representing early stages of the aggregation
pathway for the P22 tailspike protein, have been trapped
in the cold and isolated by nondenaturing polyacrylamide
gel electrophoresis [26,27]. It should be noted that the P22
tailspike protein system is an unusual one and not typical
of most globular proteins, although similar ladders of mul-
timers were observed with the P22 coat protein and car-
bonic anhydrase II [27]. Monoclonal antibodies against
tailspike chains that discriminate between folding inter-
mediates and native states were used to distinguish pro-
ductive folding intermediates and off-pathway aggregation
intermediates. The aggregation intermediates displayed
epitopes in common with productive folding intermedi-
ates, but were not recognized by antibodies against native
epitopes [55]. Because many other protein expression
systems also show increased inclusion body formation as
the temperature is raised, it is likely that ‘thermolabile’
intermediates are common precursors to inclusion bodies
at elevated temperatures. 
There are several protein systems in which it has been
shown that point mutations may dramatically affect the
amount of aggregate (inclusion body) formation; these
include the P22 tailspike protein [53], interferon-γ [56],
colicin A [57], Che Y [58], and interleukin-1β (IL-1β)
[56,59]. For example, with the human IL-1β expression
system in E. coli, the amount of inclusion body ranges
from close to 0% for the native to close to 100% for the
Leu10→Thr and Lys97→Val mutants [60]. No strong
correlations were observed between the extent of inclu-
sion body formation and either thermodynamic or thermal
stability. This and other investigations suggest that the
tendency of at least some proteins to form inclusion
bodies is related to the stability or solubility of folding
intermediates rather than native states [42]. The in vivo
effects of sequence and growth temperature of IL-1β, as
manifested by inclusion body formation, were quantita-
tively reproduced in an in vitro system, indicating not
only that inclusion body formation is based on the intrin-
sic properties of the protein sequence, but also that inter-
actions with chaperones or other cellular factors were not
significant [59].
Consistent with the proposed model, point mutations in
the hydrophobic face of the immunoglobulin light chain,
in which polar residues were introduced, significantly
decreased the fraction of inclusion body formed in an
E. coli expression system [61]. The potentially strong
dependence of inclusion body formation on point muta-
tions may also be a reflection of specificity in aggregation.
We have used attenuated total reflectance (ATR) FTIR
to examine the structure in various aggregated protein
forms, including inclusion bodies [30]. These included
all-β, all-α and α+β proteins. Some common features
were observed. First, both the inclusion bodies and the
folding aggregates exhibited substantial secondary struc-
ture, typically 50–70% of that of the native conformation.
We interpret this to mean that the inclusion bodies arose
from the association of partially folded intermediates con-
taining substantial native-like structure. Second, the
structure of a given protein in inclusion bodies, refolding
aggregates, and thermal aggregates (formed by heating a
concentrated protein solution to a temperature just below
the beginning of the thermal denaturation transition) is
the same (Figure 5). Thus, we conclude that a given
protein will have one partially folded intermediate that is
particularly prone to aggregate, and consequently most
aggregates of that protein will arise from that intermediate
and thus have similar structures.
Furthermore, in all cases, even for all-β proteins, signifi-
cant new β structure, compared to that in the native confor-
mation, was observed; typically this amounted to ~20–25%
of the total secondary structure. We take this to indicate
that the intermolecular interactions leading to the aggrega-
tion involve β-sheet-like interactions. The exact nature of
the intermolecular interactions is unknown, and could be
different in different aggregates; for example, the number
of strands in the β sheet may vary. What is clear, however,
is that aggregation usually leads to an increase in the
amount of secondary structure with IR components in the
1623–1637 cm–1 region, which corresponds to the region
where β-sheet structure is observed. Interestingly, the
amount of secondary structure in the inclusion body varies
from one protein to another, as does the amount of disor-
dered structure. Figure 5 shows the spectra of the native
inclusion body and folding aggregate forms of IL-2, illus-
trating the dramatic increase in β-sheet content compared
to the native conformation.
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Our results, along with those of Georgiou and coworkers
[44,62] on β-lactamase (see below), suggest that the gener-
ation of insoluble aggregates during refolding from denat-
urant can be considered to be an in vitro model system for
inclusion body formation. 
The secondary structure of β-lactamase (an α+β protein)
inclusion bodies in E. coli was investigated using Raman
spectroscopy [62]. The amide I band spectra of the inclu-
sion bodies were different from those of the native
protein: secondary structure estimates indicated significant
decreases in α-helical content and increases in β-sheet
content in the inclusion body samples. The structures of
the inclusion bodies were similar regardless of whether
they were localized in the cytoplasm or periplasm.
In vivo aggregates: amyloid 
A number of human diseases involve the deposition of pro-
tein aggregates; a subset of these, known as amyloidoses,
are lethal diseases involving the extracellular deposition of
amyloid fibrils and plaques. Amyloid plaque is usually
defined by three features: characteristic birefringent stain-
ing using Congo Red, fibrous morphology observed by
electron microscopy, and a distinctive X-ray fiber diffrac-
tion pattern similar to that of certain insect silks, consistent
with high β-sheet content (the so-called cross-β structure).
Amyloid fibrils are typically 7–12 nm in diameter and can
be dissociated by high concentrations of denaturant.
The molecular mechanisms leading to pathological amy-
loid formation are not well understood. In most forms of
amyloidosis the formation of amyloid appears to be caused
by a combination of factors, including high concentrations
of protein, proteolysis, mutations, and other unknown
factors. Certain other molecules are frequently found in
association with amyloid plaques, namely serum amyloid
P component [63], proteoglycans [64], apolipoprotein E
[65] and metal ions. The role of these molecules, if they
have one, in amyloid deposition is unclear at present.
There have been reports that these and other ligands may
increase or decrease aggregation (e.g. [66,67]).
Evidence to support partially folded intermediates as
amyloid fibril precursors has been found in at least two
systems. Transthyretin (TTR) is involved in two amyloid
diseases, familial amyloidotic neuropathy and senile sys-
temic amyloidosis. A partially folded monomeric interme-
diate, populated at low pH, has been implicated in in vitro
amyloid formation from transthyretin [68,69]. Recently,
two naturally occurring variants of human lysozyme have
been found to be amyloidogenic [70]. Both mutants are
significantly less stable than the wild-type protein and
have populated partially folded intermediates at 37°C that
are assumed to be the precursors of amyloid. The ther-
mally aggregated mutants showed an increased level of
β structure compared to the native conformation.
Some mutations leading to amyloid-fibril formation (in
transthyretin [71,72], lysozyme [70] and immunoglobulin
variable light, VL, chain domains [73]) are also observed to
result in decreased stability of the native state. Presumably,
in such cases there is differential destabilization of the
native conformation compared to the aggregating intermedi-
ate conformation that results in population of the aggregat-
ing conformation. It has been shown, in an in vitro system,
that point mutations may convert a non-amyloidogenic pro-
tein into an amyloidogenic one [29,73]. In Alzheimer’s
disease, the Aβ40 peptide is significantly less amyloidogenic
than the Aβ42 peptide [74]. The intermediacy of partially
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Figure 5
Aggregation results in a substantial increase in β structure compared
to the native conformation. This figure shows the second derivatives of
the FTIR spectra of the amide I region of IL-2. The aggregated forms,
inclusion bodies and folding aggregates, show 25% more β structure
than the native state. The spectra of the two aggregated forms are very
similar, indicating similar underlying secondary structure.
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folded intermediates in aggregation is also supported by
the fact that amyloid fibrils are very high in β-sheet struc-
ture, even though the corresponding native conformations
of some amyloid proteins and peptides are helical (e.g.
lysozyme [70] and the prion protein [75–78]).
Strong correlations between inclusion body formation and
mutation-dependent changes in residue hydrophobicity
were observed in the aggregation of immunoglobulin VL-
chain domains. In this case, destabilizing mutations not
only correlated with increased aggregation, but dramati-
cally different morphologies were observed from different
mutants, in one case leading to amyloid fibrils and in
another case to amorphous deposits, as found in light
chain deposition disease [73]. This suggests that specific
amino acid residue changes can control not only the onset
of aggregation disease, but also aggregate morphology and
disease type [73]. This is consistent with a study of the
propensity of Bence Jones proteins to aggregate in vitro,
which showed a very strong correlation with in vivo obser-
vations of deposition either as amyloid or light-chain
deposition disease [79]. Additional evidence that the same
polypeptide can form different kinds of aggregate mor-
phology comes from the observation that the Alzheimer’s
Aβ peptide forms ordered fibrils at pH 7.4, but amorphous
aggregates at pH 5.8 [80]. 
It has long been known that one of the structural charac-
teristics of amyloid fibrils is the presence of β-sheet struc-
ture. This is observed not only by IR spectroscopy, but
by other techniques such as solid state NMR [81] and
X-ray fiber diffraction [82–84]. For example, solid-state
13C NMR and isotope-edited IR spectroscopy investiga-
tions of the structure of amyloid formed from a fragment
of the Aβ peptide were consistent with a model of an
antiparallel β sheet with specific intermolecular align-
ment [81]. The ATR FTIR spectra of amyloid fibrils are
not noticeably different from those of disordered aggre-
gates, in that both show increased intensity in low fre-
quency components that corresponds to β structure. This
raises the possibility that there might be local order in the
apparently amorphous aggregates of inclusion bodies and
folding aggregates. For example, it is possible that the
amorphous aggregates actually involve local β-sheet for-
mation between the associating molecules, but the
ordered structure does not extend beyond the immediate
vicinity. Interestingly, it has been suggested [85] that the
β sheet in some amyloid fibrils may be in the form of a
β helix, the structure found in pectate lyase, acyltrans-
ferase and the P22 tailspike protein. The structures of
several amyloidogenic proteins and peptides can plausi-
bly be modeled by β helices to form fibrils with the
observed structural properties. The IR bands of β helices
are found in the same regions of the amide I band
(1623–1636 cm–1) as other forms of β sheet (R. Khurana
and A.L.F., unpublished observations).
Fiber diffraction studies have suggested that the ‘core’
structure of amyloid fibrils is a cross-β structure, involving
β strands running perpendicular to the axis of the fibril.
The strands interact to form β sheets with their planes
parallel to the axis of the fibril (e.g. [82–86]). A recently
proposed model by Blake and Serpell [83] for the struc-
ture of amyloid fibrils from patients with familial amy-
loidotic polyneuropathy (FAP), which are derived from
transthyretin variants, nicely accounts for the fiber diffrac-
tion patterns in aligned fibrils. The high resolution pattern
was in agreement with the cross-β structure and revealed a
new repeat of 115 Å, which can be interpreted as a repeat-
ing unit of 24 β strands that forms a complete helical turn
of the β sheet about an axis parallel to the fiber axis. Thus,
the model protofilament consists of β sheets extended in
regular helical twists along the length of the fiber.
Depending on the protein or peptide, four or five protofil-
aments intertwine to form a fibril, with the characteristic
diameter of ~10 nm. The proposed structure of the fibril
indicates that the TTR building blocks are different from
the native tetramer conformation [83].
Atomic force microscopy has been used to follow amyloid
fibril formation in vitro by Aβ40 and Aβ42 [87]. Both vari-
ants first formed small ordered aggregates (protofibrils)
that grew slowly and then rapidly disappeared, whereas
prototypical amyloid fibrils of two discrete morphologies
appeared. Aβ42 aggregated much more rapidly than Aβ40
(consistent with its relation to early onset Alzheimer’s
disease) and other in vitro studies. The protofibrils were
proposed as intermediates in the in vitro formation of fibrils.
Numerous reports of a nonfibrillar form of Aβ aggregate in
the brains of individuals who are predisposed to Alzhei-
mer’s disease suggest the existence of a precursor form,
possibly the protofibril [87]. The first reports that amyloid
fibrils can be generated in vitro (and are indistinguishable
from amyloid fibrils formed in vivo), were probably those
involving immunoglobulin light-chain domains [88,89].
In vivo aggregates: prions
The prion diseases are believed to involve a protein that
undergoes conformational changes from its normal con-
formation (PrPc or PrP-sens) to its pathological form
(PrPsc or PrP-res). The pathological form is protease resis-
tant and insoluble, usually forming amyloid fibrils [90,91].
Prions were first identified in the sheep disease scrapie
and have now been identified in, or transmitted to, a
number of mammals, including humans, and an analogous
phenomenon has been found in yeast involving the
Sup35 protein [92].
A very interesting model for prion-protein aggregation,
involving the conversion of regions of the polypeptide
that are helical in the soluble form into β sheet in the
insoluble, protease-resistant prion form, has been pro-
posed [93]. Such a conformational change is not totally
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without precedent, in the sense that a number of the pro-
teins involved in amyloidosis diseases have substantial
helical secondary structure in their native conformations,
but adopt the classical cross-β structure in the amyloid
form. What is novel with prion proteins and peptides,
however, is that it is believed that the insoluble form acts
as a template to catalyze the conversion of the soluble
form into the aggregate. An investigation of the conforma-
tion of a partially folded intermediate of the scrapie prion
protein at low denaturant concentration led to the sugges-
tion that the insoluble scrapie prion particle is an aggre-
gated form of a partially folded intermediate on the
folding pathway [78]. 
In vitro aggregates: folding aggregates 
By folding (or refolding) aggregates we refer to precipitates
that are formed when a (relatively) high concentration of
protein, unfolded in high concentration of denaturant, is
refolded by dilution of the denaturant; the vast majority of
proteins will form precipitates under such experimental
conditions, in many cases at micromolar concentrations.
Similar aggregates also occur for many proteins when (at
high concentration) they are put under relatively weak
native conditions (e.g. to a temperature close to that at the
beginning of the thermal denaturation transition, or a con-
centration of denaturant close to the beginning of the
unfolded transition).
It is most noteworthy that the ATR FTIR spectra of
refolding aggregates are essentially identical to those of
the inclusion bodies in all cases we have examined (S.
Seshadri, K.A. Oberg and A.L.F., unpublished observa-
tions). This suggests that they are formed from the same
partially folded intermediate as the corresponding inclu-
sion bodies. This is also true for aggregates formed under
weakly native conditions [30]. These observations provide
strong support for the idea that there will be one particular
partially folded intermediate for a given protein that is
particularly prone to aggregate, and that both in vivo and
in vitro aggregates of the particular protein will thus have
similar structures. 
An example of the effect of protein concentration on aggre-
gation during refolding is that of TEM β-lactamase [44]. In
this case, a partially folded intermediate in the equilibrium
denaturation was shown to correlate with aggregation:
increasing the temperature increased the amount of aggre-
gation, whereas the presence of sucrose decreased the
amount of aggregation. This in vitro data closely paralleled
in vivo observations on β-lactamase inclusion body forma-
tion [62]. A partially folded intermediate in the refolding of
carbonic anhydrase was initially shown to form dimers and
then higher oligomers before forming insoluble aggregates
[94,95]. Low temperatures and low protein concentrations
were shown to facilitate the refolding of rhodanese, mini-
mizing aggregation due to a partially folded intermediate
[96]. Another system in which concentration-dependent
aggregation revealed evidence for partially folded interme-
diates as the source of the aggregation is that of reduced-
denatured lysozyme [97]. Disulfide formation has been
shown to be an important factor in the aggregation occur-
ring during the renaturation of denatured-reduced lyso-
zyme: aggregation was shown to compete with productive
folding from a partially folded intermediate [97–99].
In vitro aggregates: thermally gelled proteins
It has long been known that heating solutions of many
proteins results in the formation of gels, due to aggrega-
tion of the protein. Biophysical studies have shown that
these gels have a large component of β-sheet structure,
and FTIR studies indicate the preponderance of a band
in the vicinity of 1616 cm–1 (attributed to antiparallel
β sheet; [18,100,101]). Evidence that these thermally
induced aggregates arise from partially folded intermediates
has been presented (e.g. [102]).
In vitro aggregates: partially folded intermediates 
We have examined the structure of partially folded inter-
mediates (A states) of apomyoglobin [103] at low pH in
the monomeric and aggregated (at higher protein concen-
tration) states (K.A. Oberg and A.L.F., unpublished obser-
vations). The FTIR spectra reveal increased β structure in
the aggregated forms: the intensity of the β-sheet band(s)
increases with increasing protein concentration (Figure 6).
Kinetics of protein aggregation
The kinetics of aggregation have most commonly been
monitored by light scattering (e.g. [104,105]). Depending on
the particular system, the observed kinetics range from first
order to complex. Typically, however, there is an initial lag,
followed by an exponential growth phase (e.g. [7,106–109]).
Such kinetic phenomena have been observed for both amor-
phous and ordered (amyloid) aggregate formation, and are
usually attributed to a nucleation–polymerization process.
Several kinetic models for protein aggregation have been
put forward, including those accounting for the competi-
tion between folding and aggregation [109,110], amyloid
formation [105,111,112] and prion formation [106], and
specific systems, such as carbonic anhydrase [95] and
β-lactoglobulin [113]. In amyloid formation, the kinetic
issue can be broken down into fibril formation and fibril
growth; two general models have been proposed: nuclea-
tion-dependent polymerization [74,112] and diffusion-
limited aggregation [107]. Data supporting both models
have been reported, but most are more in accord with the
nucleation-growth model [114–116]. A recent review sum-
marizes the supporting evidence for a nucleation-dependent
polymerization mechanism [108]. 
During the biosynthesis of proteins and during in vitro
refolding, protein aggregation is in kinetic competition with
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other processes (especially folding to the native state) and
in vivo protein aggregation is in kinetic competition with
association with molecular chaperones (Figure 4). The out-
come of this competition is highly sensitive to the particu-
lar conditions; for example, the protein concentration and
the lifetime of the intermediate. One of the first detailed
studies of the competition between in vitro folding and
aggregation was that of the tetramer lactate dehydrogenase
[117,118]. There have been few studies of the kinetics of
partitioning between folding and inclusion body formation
in vivo. Using radiolabeling in the Che Y overexpression
system in E. coli, however, it was demonstrated that the
kinetics of aggregation were consistent with aggregation
arising predominantly from a partially folded intermediate
[119]. Studies on the kinetics of formation of amyloid
fibrils from Aβ peptide indicate that the rate of fibril for-
mation is very sensitive to the experimental conditions as
well as sample preparation [120]. A recent report suggests
that an amorphous aggregate intermediate stage might be
important in the formation of amyloid fibrils [121].
Aggregation can induce secondary structure
Recently, in studies on partially folded intermediates of
staphylococcal nuclease (SNase) we have discovered a
rather interesting phenomenon, namely that aggregation
of a partially folded intermediate may induce substantial
additional secondary structure in the protein (V.N.
Uversky and A.L.F., unpublished observations). Staphylo-
coccal nuclease, like many proteins [32,122], forms par-
tially folded intermediates at low pH and low ionic
strength [123]. Under these conditions and low protein
concentrations (< 0.2 mg/ml) SNase is monomeric, and
~50% folded, based on the amount of secondary structure
and the radius of gyration from small-angle X-ray scatter-
ing studies. Increasing the protein concentration leads to
the formation of dimers, with a significant increase in sec-
ondary structure (corresponding to ∼70% of that of the
native state). Further increases in protein concentration
induced a second transition leading to the formation of
larger (multimeric) soluble aggregates with more sec-
ondary structure. Above 4 mg/ml protein the far-UV CD
spectrum is almost identical to that of the native protein.
This apparently native-like conformation has a near-UV
CD spectrum close to that of the unfolded molecule,
however. The Kratky plot of the small-angle X-ray scatter-
ing data for the monomeric intermediate is very similar to
that for the unfolded protein, indicating a lack of globular-
ity, but as the protein concentration increases the Kratky
plots show increasing amounts of globular structure. Thus,
the increase in concentration of the partially folded inter-
mediate induces the appearance of new internal structure,
as manifested by both increased secondary structure and
the globular core. It is not clear how widespread this phe-
nomenon may be, but at least one other example exists:
the formation of filamentous helical structures of a
peptide consisting of the first 24 residues of barnase [124].
Immediately after dissolving the peptide fragment in
aqueous solution CD spectroscopy indicates a random coil
structure, but over time aggregation occurs leading to the
formation of aggregated helices.
Molecular chaperones and protein aggregation
Molecular chaperones comprise several families of stress
(heat shock) proteins that bind unfolded proteins or par-
tially folded intermediates. In particular, the hsp70 and
hsp60 families have been shown to facilitate protein
folding in vivo and in vitro [125]. Current understanding of
the role of hsp70 in protein folding suggests that the chap-
erone sequesters the unfolded or partially folded protein,
thereby preventing its aggregation. The chaperone does
not, however, actively participate in the folding process:
binding of ATP (which subsequently becomes hydrolyzed)
leads to release of the substrate protein in a non-native
conformation [126–129]. Recent studies on the E. coli
hsp60, GroEL, and its eukaryotic homologs, suggest that
protein folding may be facilitated by a mechanism in which
the chaperone binds a partially folded intermediate (or a
partially folded domain of a large multidomain protein) in
its large hydrophobic cavity. A subsequent conformational
change induced by binding ATP leads to a much more
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Figure 6
The FTIR amide I absorbance spectra of a partially folded intermediate
of the helical protein apomyoglobin in the monomeric and aggregated
states (aggregation was induced by high protein concentration). The
aggregate shows a large increase in β structure (arrow) due to the
aggregation.
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polar environment. Folding can thus occur in a situation
where aggregation is precluded; multiple rounds of binding
and release may occur [129–133].
The longer a protein takes to fold spontaneously, the
longer it is likely to remain associated with the hsp60 and
hsp70 chaperones. Some proteins fold fast and may have
partially folded intermediates that have little propensity to
aggregate, thus requiring little or no chaperone assistance,
and little tendency to form inclusion bodies [134]. Evi-
dence to support the notion that both the conformation and
the lifetime of the intermediate are critical is found in the
observation that hsp70 binds only to the initially collapsed
partially folded intermediates of cytosolic and mitochondr-
ial aspartate aminotransferase. The intermediate of the
cytosolic enzyme has a much shorter lifetime than its mito-
chondrial homolog, which leads to decreased chaperone
binding in the case of the cytosolic protein [135].
Several experiments have been conducted in which over-
expression of various combinations of the DnaK and
GroEL chaperone systems decreases the amount of aggre-
gation of either a model protein (e.g. human growth
hormone, hGH [136], or a β-galactosidase fusion protein
[133]) or of the total cell proteins [137]. In addition, in vitro
experiments in which the yield of soluble or native protein
for aggregating systems is increased in the presence of
various chaperones have been reported (e.g. [138–141]).
There have been conflicting reports as to whether the
DnaK or GroEL systems, individually or together, yield
the optimal amount of renaturation. It appears that in some
cases all the chaperones are required for maximal suppres-
sion of aggregation whereas in other systems either only
the DnaK system or the GroEL system alone was effective
[142]. It is most likely that the two systems interact at dif-
ferent stages of folding and thus different results may be
observed depending on intermediate lifetimes etc. [138].
Little is known about the interplay between molecular
chaperones and amyloid formation, but it is reasonable to
assume that chaperones are significant in preventing
amyloid formation in vivo by preventing aggregation of the
precursor partially folded intermediates. It is possible, by
analogy with the situation we postulate for inclusion body
formation, that a lack of available chaperones is important
in amyloidosis. Because amyloid deposits are extracellular,
some limitations may be placed on the accessibility of
amyloid fibrils (or their precursors) to chaperones.
Prevention of aggregation
There are probably two common reasons for the formation
of aggregates during renaturation: exceeding the solubility
limit of a partially folded intermediate, and the presence of
intramolecular misfolding due to the nature of the
expressed protein — for example due to multiple domains.
The problem of exceeding solubility is explained by solu-
bility phase diagrams, which also suggest a solution. For
instance, a phase diagram for the solubility of apomyo-
globin as a function of urea and protein concentration
showed that the solubility was a minimum near the Cm
(denaturant concentration at the midpoint of the unfold-
ing transition). Because the solubility of both polar and
non-polar molecules increases in the presence of low con-
centrations of urea, the observed decrease in apomyoglo-
bin solubility is due to the population of either denatured
or partially folded intermediate states [34]. Subsequent
investigation of the structure of the precipitated material
by ATR FTIR indicated the presence of substantial
α helix, consistent with the insolubility arising from the
population of partially folded intermediates. Phase dia-
grams such as the one described explain the frequent
problems in renaturing inclusion bodies from concen-
trated denaturant: a simple dilution of a concentrated
protein solution in high denaturant crosses through the
region where the solubility limit is exceeded, and this
leads to precipitation. Precipitation can be avoided by
first diluting the protein concentration to a level such that
as the denaturant concentration is decreased the solubil-
ity limit is not exceeded. Unfortunately, in many cases
this is not a practical solution, although procedures for the
large (industrial) scale renaturation of inclusion bodies
dissolved in high concentrations of denaturant have been
developed that involve maintaining the concentration of
partially folded intermediates very low in order to avoid
their aggregation [143,144]. Additional factors also appear
to be involved in some cases.
Several other methods have been suggested or shown to
prevent or decrease aggregation, ranging from ligands that
stabilize the native state [145,146] to the presence of
competing peptides [40]. Although there are, as yet, no
general methods that can be applied to prevent aggrega-
tion, there are a number of strategies that are frequently
successful [94,143–147]. The most popular approaches
currently involve chaperones [148,149], immobilization
[16,150], low concentration, stabilizing agents such as
arginine [143], optimization of growth conditions, and the
use of fusion proteins [151]. Most of these can be readily
rationalized based on our current understanding of the
factors involved in protein aggregation. In essence, most
factors that increase the partitioning of partially folded
intermediates towards the native conformation, rather
than towards aggregated species, are effective. 
Immobilization of the unfolded protein (thereby prevent-
ing aggregation by allowing each molecule to fold indepen-
dently) and subsequent renaturation has been successfully
used as a means of preventing aggregation [150]. This
approach may not work for oligomeric proteins, and may
not work so well for some multidomain proteins. A system
of artificial chaperones (detergents and cyclodextrin) has
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been successfully used to minimize aggregation in the
renaturation of denatured-reduced lysozyme [152]. The
application of molecular chaperones to facilitate the renatu-
ration of recombinant proteins has recently been reviewed
[149]. There have been a number of reports indicating
that osmolytes and other stabilizing ligands (kosmotropes
[153]) may decrease the amount of aggregation; this proba-
bly reflects differential stabilization of the native state
[5,46]. Interestingly, osmolytes have been shown to inhibit
prion formation in the scrapie system, consistent with
the involvement of protein conformation changes in the
formation of prions [154].
The observation that lower growth temperatures often
lead to decreased inclusion body formation may be ratio-
nalized on the basis of the slower rate of protein synthe-
sis, changes in the level of cell stress (which could lead to
changes in the amount of available chaperones), the
decreased rate of aggregation at lower temperature, and
decreased hydrophobic interactions. These properties
have been developed into a strategy for circumventing
aggregation using temperature jumps [155].
Several strategies for decreasing amyloid fibril formation
have been proposed or demonstrated [156–158], and these
are summarized in a recent review [158]. Because the rate
of amyloid formation is usually greatly enhanced by seeding
[108], prevention of amyloid seeds will delay the onset of
amyloid formation [159]. The addition of ligands that bind
specifically to the native state of TTR inhibited the forma-
tion of TTR amyloid fibrils, presumably by stabilizing the
native state [146].
Conclusions
Our current understanding of protein aggregation (of the
pathological type) may be summarized as follows. It is the
amino acid sequence that ultimately determines the
propensity for aggregation, modulated by the environ-
mental conditions. Aggregates are most commonly
formed from the interaction of partially folded intermedi-
ates containing significant native-like structure. These
interactions involve extended chain or β-sheet-like con-
formations. Thus, both ordered and disordered aggregates
show increased β structure relative to the native confor-
mation (in the case of all-β proteins, the increased β struc-
ture is distinct from that of the native protein).
Regardless of the manner formed (in vivo or in vitro),
aggregates of a given protein will probably have similar
structure and arise from a common intermediate. It is
likely that aggregation normally involves specific inter-
molecular interactions; among other consequences, this
means that aggregates are usually quite homogeneous and
that aggregation will be very sensitive to mutations in the
protein. The process of aggregation itself may induce
additional structure in the precursor intermediates. After
the amino acid sequence, the next most critical factor
determining aggregation is the concentration of the protein
(specifically the aggregating partially folded intermediate).
Factors that increase the concentration (population) of
partially folded intermediates will also increase the propen-
sity for aggregation. In vivo, molecular chaperones are
very important for preventing intracellular aggregation,
especially during the folding of newly synthesized proteins.
There are still many outstanding and critical questions
regarding protein aggregation. Among these are questions
about the detailed mechanism of the aggregation process,
factors determining the kinetics of aggregation, the struc-
tural nature of the intermolecular interactions, and how
aggregation may be effectively and efficiently prevented,
especially in vivo. Experimentally, the unambiguous deter-
mination of whether specificity is shown in co-aggregating
systems is a very challenging problem and has not yet been
adequately addressed.
Note added in proof
The reader is also directed to Adv. Protein Chem. 50 (1997), which was
published after completion of the writing of this review and is devoted to
protein misassembly.
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